|
Primary Myelofibrosis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Luspatercept (and sotatercept), ligand traps that particularly inhibit GDF11, lead to RBC transfusion independence in 10% to 50% of lower-risk MDSs resistant to available treatments, and have started to be used in PMF.
|
30602619 |
2019 |
|
Anaplasia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Correspondingly, TSA treatment was shown to decrease GDF11 expression and reverse CASMC dedifferentiation in the partial ligated carotid artery of mice.
|
30462553 |
2019 |
|
Aplastic Anemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
GDF11 is increased in patients with aplastic anemia.
|
30727851 |
2019 |
|
Anorexia Nervosa
|
0.010 |
Biomarker
|
disease |
BEFREE |
Serum GDF8, GDF11 and BMD were determined in 25 girls (12-16 years old) with AN and 31 healthy girls (12-16 years old).
|
30281844 |
2019 |
|
Cardiac Arrhythmia
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
We found that GDF11 reduced arrhythmia severity and successfully attenuated myocardial infarction; GDF11 also increased cardiac function after I-R, enhanced HO-1 expression and decreased oxidative damage.
|
30900023 |
2019 |
|
Arthritis
|
0.010 |
Biomarker
|
disease |
BEFREE |
This study presents GDF11 as a potential target for the treatment of inflammatory arthritis, including RA.-Li, W., Wang, W., Liu, L., Qu, R., Chen, X., Qiu, C., Li, J., Hayball, J., Liu, L., Chen, J., Wang, X., Pan, X., Zhao, Y. GDF11 antagonizes TNF-α-induced inflammation and protects against the development of inflammatory arthritis in mice.
|
30407878 |
2019 |
|
Rheumatoid Arthritis
|
0.010 |
Biomarker
|
disease |
BEFREE |
This study presents GDF11 as a potential target for the treatment of inflammatory arthritis, including RA.-Li, W., Wang, W., Liu, L., Qu, R., Chen, X., Qiu, C., Li, J., Hayball, J., Liu, L., Chen, J., Wang, X., Pan, X., Zhao, Y. GDF11 antagonizes TNF-α-induced inflammation and protects against the development of inflammatory arthritis in mice.
|
30407878 |
2019 |
|
Dermatitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Collectively, GDF11 may represent a promising molecular target for the prevention and treatment of psoriasis-like skin inflammation.
|
30259241 |
2019 |
|
Heart Diseases
|
0.010 |
AlteredExpression
|
group |
BEFREE |
GDF11 levels were not related to the presence of hypertension or cardiopathy.
|
31248139 |
2019 |
|
Hypertensive disease
|
0.010 |
AlteredExpression
|
group |
BEFREE |
GDF11 levels were not related to the presence of hypertension or cardiopathy.
|
31248139 |
2019 |
|
Acute myocardial infarction
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The decline in circulating count and survival of VEGFR2<sup>+</sup>/CD133<sup>+</sup> cells with age was accompanied by decrease in their TERT and GDF11 expression levels in patients with AMI.
|
31292540 |
2019 |
|
Tumor Progression
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
We also demonstrate that CRC-associated human intestinal lymphatic endothelial cells regulate tumor cell growth via growth differentiation factor 11, a soluble matrisome component which in CRC patients was found to be associated with tumor progression.
|
30889293 |
2019 |
|
Uveal melanoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
High GDF11 expression was associated with uveal melanoma in advanced stages (IV), epithelioid cell dominant subtype, as well as extrascleral extension.
|
30883611 |
2019 |
|
Fibrosis, Liver
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We showed that the expression of GDF11 is upregulated in patients with liver fibrosis and in experimentally induced murine liver fibrosis models.
|
31767630 |
2019 |
|
congenital lobulation of kidney
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
A variant in GDF11 (encoding growth differentiation factor 11), predicting a p.(Arg298Gln) substitution at the Furin protease cleavage site, was identified in one family that segregated with CL/P and both rib and vertebral hypersegmentation, mirroring that seen in Gdf11 knockout mice.
|
31215115 |
2019 |
|
Chronic liver disease
|
0.010 |
Biomarker
|
group |
BEFREE |
Collectively, our findings uncover a protective role of GDF11 during liver fibrosis and suggest a potential application of GDF11 for the treatment of chronic liver disease.
|
31767630 |
2019 |
|
Neurodegenerative Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
The identification of GDF11 as a "rejuvenating factor" opens up perspectives for the treatment of neurodegenerative diseases.
|
31330871 |
2019 |
|
Sarcopenia
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Thus, treatment with GDF11 propeptide may be a potential therapeutic strategy for diseases associated with muscle atrophy like sarcopenia and the muscular dystrophies.
|
31133057 |
2019 |
|
Liver carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
GDF11 has been poorly investigated in cancer, particularly in those with stemness capacity, such as hepatocellular carcinoma (HCC), one of the most aggressive cancers worldwide.
|
30890427 |
2019 |
|
Inflammatory dermatosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Collectively, GDF11 may represent a promising molecular target for the prevention and treatment of psoriasis-like skin inflammation.
|
30259241 |
2019 |
|
Hypertrophic Cardiomyopathy
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Therefore, the current study aimed to examine the effects of GDF11 on ANG II-induced hypertrophic cardiomyopathy and expression of ANP, BNP and beta-MHC in mice, and explore possible molecular mechanisms.
|
30714521 |
2018 |
|
Cerebral Infarction
|
0.010 |
Biomarker
|
disease |
BEFREE |
However, in addition to its role in aging, the relationship between GDF11 and cerebral ischemia is still an important area that needs more investigation.
|
29432795 |
2018 |
|
Colitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our aim is to determine whether GDF11 has an effect on attenuating experimental colitis in mice.
|
30188752 |
2018 |
|
Ulcerative Colitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Thus, our research shows that GDF11 alleviates DSS-induced colitis by inhibiting NLRP3 inflammasome activation, providing some basis for its potential use in the treatment of UC.
|
30188752 |
2018 |
|
Diabetes
|
0.010 |
Biomarker
|
disease |
BEFREE |
These findings suggest that GDF11 repletion may enhance EPC resistance to diabetes-induced damage, improve angiogenesis, and thus, increase blood flow.
|
30026260 |
2018 |